Rituximab treatment results in impaired secondary humoral immune responsiveness
作者： Lizet E. van der Kolk , Joke W. Baars , Martin H. Prins , Marinus H. J. van Oers
DOI: 10.1182/BLOOD.V100.6.2257
关键词:
摘要: In lymphoma patients, treatment with chimeric CD20 monoclonal antibodies (rituximab) results in a depletion of normal and malignant B cells, persisting for 6 to 9 months. This B-cell leads neither decrease immunoglobulin levels nor an increase the number infectious complications. However, effect rituximab on immune responsiveness is unknown. 11 patients relapsed, low-grade lymphoma, we investigated humoral response 2 primary antigens recall antigens. After treatment, was significantly decreased when compared before treatment. Already none these able mount These findings are relevant regarding feasibility maintenance may also offer rationale antibody-mediated autoimmune diseases rituximab.
ashpublications.org
bloodjournal.org参考文章(10)
Frank J. Hsu, Clemens B. Caspar, Debra Czerwinski, Larry W. Kwak, Tina Marie Liles, Athanasia Syrengelas, Behnaz Taidi-Laskowski, Ronald Levy, Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial Blood. ,vol. 89, pp. 3129- 3135 ,(1997) , 10.1182/BLOOD.V89.9.3129
P McLaughlin, A J Grillo-López, B K Link, R Levy, M S Czuczman, M E Williams, M R Heyman, I Bence-Bruckler, C A White, F Cabanillas, V Jain, A D Ho, J Lister, K Wey, D Shen, B K Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology. ,vol. 16, pp. 2825- 2833 ,(1998) , 10.1200/JCO.1998.16.8.2825
Paul Albrecht, G. van Steenis, A. L. van Wezel, Jonas Salk, Standardization of Poliovirus Neutralizing Antibody Tests Clinical Infectious Diseases. ,vol. 6, ,(1984) , 10.1093/CLINIDS/6.SUPPLEMENT_2.S540
Jette Victor, Jenny Dahl Knudsen, Lars P. Nielsen, Anders Fomsgaard, Søren Thybo, Ib Bygbjerg, Henrik Westh, Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted Vaccine. ,vol. 12, pp. 1327- 1329 ,(1994) , 10.1016/S0264-410X(94)80028-X
Kees Korver, Wim P. Zeijlemaker, Peter Th.A. Schellekens, Jaak M. Vossen, Measurement of primary in vivo IgM- and IgG-antibody response to KLH in humans: implications of pre-immune IgM binding in antigen-specific ELISA. Journal of Immunological Methods. ,vol. 74, pp. 241- 251 ,(1984) , 10.1016/0022-1759(84)90291-6
Peter McLaughlin, Rituximab: perspective on single agent experience, and future directions in combination trials Critical Reviews in Oncology Hematology. ,vol. 40, pp. 3- 16 ,(2001) , 10.1016/S1040-8428(01)00130-5
Voravit Ratanatharathorn, Erik Carson, Christopher Reynolds, Lois J Ayash, John Levine, Gregory Yanik, Samuel M Silver, James LM Ferrara, Joseph P Uberti, Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease Annals of Internal Medicine. ,vol. 133, pp. 275- 279 ,(2000) , 10.7326/0003-4819-133-4-200008150-00011
G W King, B Yanes, P E Hurtubise, S P Balcerzak, A F LoBuglio, Immune function of successfully treated lymphoma patients. Journal of Clinical Investigation. ,vol. 57, pp. 1451- 1460 ,(1976) , 10.1172/JCI108415
G.C. De Gast, M.R. Halie, H.O. Nieweg, Immunological responsiveness against two primary antigens in untreated patients with Hodgkin's disease. European Journal of Cancer. ,vol. 11, pp. 217- 224 ,(1975) , 10.1016/0014-2964(75)90001-8
Mark K Slifka, Rustom Antia, Jason K Whitmire, Rafi Ahmed, None, Humoral immunity due to long-lived plasma cells Immunity. ,vol. 8, pp. 363- 372 ,(1998) , 10.1016/S1074-7613(00)80541-5